- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06914427
PET/CT Imaging Study With Simultaneous Dual-nuclide Imaging Technique
This is a study using a self-control approach and is expected to recruit 35 volunteers, including prostate cancer patients, neuroendocrine tumour patients, glioma patients, lung cancer patients, and normal volunteers, to undergo dual-tracer PET/CT imaging and to validate the separation performance and quantitative accuracy of simultaneous dual-tracer imaging in humans.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Qiqi Yang Qiqi Yang
- Phone Number: 0086+18992601101
- Email: yangqiqi_1101@163.com
Study Locations
-
-
Shaanxi
-
Xi'an, Shaanxi, China
- Recruiting
- Department of Nuclear Medicine,Xijing Hospital, Fourth Military Medical University
-
Contact:
- Qiqi Yang Qiqi Yang
- Phone Number: 0086+18992601101
- Email: yangqiqi_1101@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age: 18 ~75 years old (including boundary values);
- Gender: male or female;
- Normal volunteers: males weighing ≥50kg, females weighing ≥45kg, and body mass index [BMI = weight (kg)/height 2 (m2)] within the range of 19.0 ~ 26.0kg/m2 (including borderline values);
- patients with prostate cancer: patients with pathologically-confirmed biochemical relapsed or primary diagnosed prostate cancer with highly suspected systemic metastases on conventional imaging or PSA levels;
- patients with neuroendocrine tumour patients: patients with NET (G2-G3) or NEC confirmed by pathology and highly suspected of having more than 3 metastases by conventional imaging;
- patients with glioma:patients with glioma confirmed by pathology or highly suspected by enhanced MRI and proposed to undergo surgical resection; patients with Lung cancer: patients with lung cancer or suspected recurrent lung cancer.
- Subjects can fully understand and voluntarily participate in this experiment and sign an informed consent form.
Exclusion Criteria:
- Those who cannot tolerate intravenous drug delivery methods (e.g., history of needle and blood sickness);
- those with alcohol allergy;
- and those who, in the opinion of the investigator, are unsuitable to undergo or are unable to complete imaging studies such as PET for specific reasons;
- Under 18 years of age or ECOG score > 2;
- Less than 1 month after completion of radiotherapy and less than 2 months after completion of octreotide treatment in patients with neuroendocrine tumours;
- Women during pregnancy and breastfeeding;
- Practitioners requiring prolonged exposure to radioactive conditions;
- Serious diseases of heart, kidney, lung, vascular, nervous and mental systems, immunodeficiency diseases and hepatitis/cirrhosis;
- Participation in other interventional clinical trials within 1 month prior to screening;
- Presence of other conditions that, in the opinion of the investigator, make participation in this study unsuitable.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: before-after study in the same patient
Approximately 35 volunteers are planned to be included in this study. The screened subjects will be scanned with a mononuclide 68Ga/124I labeled tracer on the first day, a mononuclide 18F labeled tracer on another day, and a dual-nuclide 68Ga/124I +18F tracers on another day, to validate the separation performance and quantitative accuracy of simultaneous dual-tracer imaging method in humans. |
Scanning time: acquisition starts 60±10 minutes after 68Ga/18F labeled tracer injection; 124I labeled tracer around 24h after injection; Scanning parameters: whole-body imaging (cranial vault to mid-thigh), routine single-nuclide 3 min/bed; dual-nuclide 5-15min/bed. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Signal retention
Time Frame: 1 day from injection of the tracer
|
using the 68Ga, 124I, 18F individual imaging images as the gold standard and calculating the retention of the letter lesion area number on the 68Ga/18F and 124I/18F separate images |
1 day from injection of the tracer
|
|
Clearance
Time Frame: 1 day from injection of the tracer
|
calculated by using the 68Ga, 124I and 18F individual imaging images as the gold standard, and calculating the signal clearance of the lesion area on the 18F/68Ga and 18F/124I separate images |
1 day from injection of the tracer
|
|
SUVmax difference values
Time Frame: 1 day from injection of the tracer
|
paired t-test comparing the difference in SUVmax values of lesions on gold standard versus 68Ga/18F and 124I/18F separation images |
1 day from injection of the tracer
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Genital Neoplasms, Male
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Genital Diseases, Male
- Prostatic Diseases
- Male Urogenital Diseases
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Lung Diseases
- Neoplasms, Glandular and Epithelial
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Prostatic Neoplasms
- Lung Neoplasms
- Glioma
- Neuroendocrine Tumors
- Diagnostic Techniques and Procedures
- Diagnosis
- Tomography
- Diagnostic Imaging
- Radiography
- Image Interpretation, Computer-Assisted
- Radiographic Image Enhancement
- Image Enhancement
- Photography
- Tomography, X-Ray
- Tomography, Emission-Computed
- Radionuclide Imaging
- Diagnostic Techniques, Radioisotope
- Positron-Emission Tomography
- Tomography, X-Ray Computed
- Multimodal Imaging
- Positron Emission Tomography Computed Tomography
Other Study ID Numbers
- KY20252098-F-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.